BTL will present its latest portfolio of non-invasive and minimally invasive aesthetic technologies at the Non-Surgical Symposium 2026, with a focus on integrated treatment approaches across facial aesthetics, body, pelvic health and wellness technology.
The BTL team will be on stand throughout the event, showcasing EMFACE, EMFUSION, EXION, EMSELLA and EXOMIND, and inviting delegates to learn more about the company’s evolving device portfolio and clinical applications.
A key focus for BTL at NSS 2026 will be its “trifecta” campaign, highlighting the role of EMFACE, EXION and EMFUSION within contemporary aesthetic treatment planning.
The campaign brings together BTL technologies across facial muscle stimulation, radiofrequency- based skin and tissue procedures, and advanced energy-based aesthetic protocols, reflecting the growing demand for multimodal treatment strategies in clinic settings.
BTL will also be joined at NSS by Dr Andrew Clark, a cosmetic medicine doctor who runs two busy cosmetic medicine clinics in Perth, Western Australia. Dr Clark holds roles as an International Key Opinion Leader and Medical Adviser for several major dermal filler, cosmetic laser and device companies, and is frequently invited to speak at major conferences throughout Australasia and Europe. In addition to his medical degree, Dr Clark has earned a PhD in skin and muscle biochemistry and is an advocate for using peer-reviewed scientific evidence to guide decision-making in aesthetic medicine. He is also a Board Member and Treasurer of the Australasian College of Aesthetic Medicine. At NSS 2026, Dr Clark will speak on two key BTL technologies:
EMFACE: Why treating facial muscles changes ageing.
EXION: Safe fractionated RF microneedling in an era of fat loss and fear.
Dr Clark will also be available on the BTL stand, giving delegates the opportunity to connect directly and discuss clinical experience, treatment planning and device-led approaches.
Brody Cook, National Sales Manager, BTL Aesthetics ANZ, said NSS is an important opportunity for practitioners to engage directly with the company’s technologies and clinical team.
“BTL is looking forward to connecting with practitioners at NSS 2026 and showcasing the breadth of our device portfolio,” said Cook.
“This year, our focus is on helping clinics understand how technologies such as EMFACE, EXION and EMFUSION can work together as part of an integrated treatment approach. NSS provides a valuable platform for education, conversation and hands-on engagement with the technologies shaping the future of aesthetic practice.”
BTL representatives will be available on stand throughout NSS 2026, with delegates invited to visit the team to learn more or book a meeting.
For more information on Dr Andrew Clark, visit: miraclinic.com.au



